

## REMARKS

Claims 10-20 were examined. Claims 10, 14, and 18 are amended. Claims 10-20 remain in the Application.

### Claims Rejected under 35 U.S.C. §102(a)

The Patent Office rejects claims 10-20 under 35 U.S.C. §102(a) as being anticipated by Chein (GB2320190) ("Chein '190"). Applicant respectfully traverses the rejection.

In order to anticipate a claim, the relied upon reference must disclose every limitation of the claim. Among other limitations, Applicant's independent claims 10 and 14 describe a kit comprising amounts of human growth hormone, thyroid hormone, and at least one of the supplemental hormones for replenishment to physiological levels for a human subject afflicted with multiple sclerosis. Claim 18 describes a kit comprising human growth hormone, pregnenolone, and thyroid hormone. A relevant difference between an otherwise healthy human subject and one afflicted with multiple sclerosis (MS) lies in body temperature. For hormone administration, the body temperature in a subject afflicted with MS should be titrated to an early morning, upon rising body temperature of greater than 97.6 Fahrenheit and an afternoon body temperature of greater than 98.6 Fahrenheit. If these temperatures are not reached, at least the T3 (thyroid) hormone dosage has to be increased until the temperature is reached, even though it may reach a level exceeding the physiological level for an otherwise healthy human subject.

For at least the above stated reasons, Applicant respectfully requests that the Patent Office withdraw the rejection of independent claims 10, 14 and 18 over Chein '190.

Claims 11-13 depend from claim 10. Claims 15-17 depend from claim 14. Claims 19 and 20 depend from claim 18. Accordingly, Applicant respectfully requests that the Patent Office withdraw the rejection of dependent claims 11-13, 15-17, 19 and 20 for at least the same reasons stated above regarding independent claims 10, 14 and 18, respectively.

### CONCLUSION

In view of the foregoing, it is believed that all claims now pending (1) are in proper form, (2) are neither obvious nor anticipated by the relied upon art of record, and (3) are in condition for allowance. A Notice of Allowance is earnestly solicited at the earliest possible date. If the Patent Office believes that a telephone conference would be useful in moving the Application forward to allowance, the Patent Office is encouraged to contact the undersigned at (310) 207-3800.

If necessary, the Commissioner is hereby authorized in this, concurrent and future replies, to charge payment or credit any overpayment to deposit account 02-2666 or any additional fees required under 37 C.F.R. §§ 1.16 or 1.17, particularly, extension of time fees.

Respectfully submitted,

BLAKELY, SOKOLOFF, TAYLOR & ZAFMAN LLP

Dated: 8/26/04

William T. Babbitt

William Thomas Babbitt, Reg. No. 39,591

12400 Wilshire Boulevard  
Seventh Floor  
Los Angeles, California 90025  
(310) 207-3800

I hereby certify that this correspondence is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Nedy Calderon

Nedy Calderon

8/26/04  
Date